A series of promotions has been announced at US biopharmaceutical company Nektar Therapeutics (Nasdaq: NKTR).
The three researchers who have been promoted to leading positions at the West coast company have more than 60 years of experience between them in pharma and biotech.
"With the growth in the development of Nektar's I-O portfolio and our submission of an NDA filing for NKTR-181, it is critical that we have the right leadership in place"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze